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Abstract
Purpose: Myeloid-derived suppressor cells (MDSC) have emerged as an immune-regulatory cell type that is expanded in tumor-bearing mice, but less is known about their immune-suppressive role in cancer patients.
Experimental design: To study the importance of MDSC in patients with melanoma, we characterized the frequency, phenotype and suppressive function of blood myeloid-derived cells and tumor-infiltrating myeloid cells in 26 freshly resected melanomas. 
Introduction
Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of myeloid-derived cells which are greatly expanded in experimental models of cancer (1) (2) (3) . Both monocytic (CD11b + Ly6C + Ly6G -) and granulocytic (CD11b + Ly6C -Ly6G + ) myeloid-derived suppressor cells have been described in murine tumor models and their unique distinctive trait compared to cells with similar phenotype in healthy mice is their ability to suppress T cell responses in vitro and in vivo (4) (5) (6) (7) , in part through interfering with L-arginine metabolism (8) . Knowledge of MDSC has been primarily established in preclinical models and the phenotypic diversity of MDSC as well as the lack of common markers to study these cells in mice and humans has generated ambiguity in their characterization in cancer patients. The nature, distribution, frequency, and the contribution of their suppressive phenotype in patients with cancer is highly debated. immune-suppressive function have been found to be increased in patients with renal cell carcinoma (13, 14) , HCC (15) , NSCLC (16) , glioblastoma (17) , gastrointestinal (18, 19) , and prostate cancer (20) . MDSC have also been shown to suppress NK cell function in addition to T cell function(21). In the particular case of metastatic melanoma, both monocytic (22) (23) (24) as well as granulocytic (25) blood MDSC with immunesuppressive function have been studied independently and proposed to exert an immune-regulatory role.
The immune-suppressive activity of MDSC is highly dependent on cell-to-cell contact suggesting that their most important role in dampening tumor-specific T cell responses is more likely to be at the tumor site, where they have been found to accumulate in murine tumor-bearing models. Additionally, the ability of myeloid cells to suppress T cell responses can be potentiated in the hypoxic tumor microenvironment through an increase in the expression of Arginase I and iNOS via signaling through hypoxia inducible factor 1 alpha (4, 26 melanoma tumor model were capable of reducing T cell proliferation to 40% relative to absence of MDSC (100%) and more efficiently than MDSC from bone marrow (70%) (27) . Moreover, the suppression exerted by MDSC from a transplantable prostate tumor model was greater in MDSC from the tumor site compared to MDSC from peripheral tissues (28) . In spite of recurrent evidence supporting superior in vitro suppressive activity of tumor-infiltrating myeloid cells in murine models(6) most human studies of MDSC have focused on peripheral blood and bone marrow (29) and thus, the frequency and actual immuneregulatory role of human tumor-infiltrating myeloid cells is largely unexplored. A population of granulocytic myeloid cells (CD11b + CD14 -) infiltrating three human head and neck tumors was capable of suppressing non-specific T cell proliferation compared to the homologous population from peripheral blood(4). Ovarian carcinomas, in the other hand, recruit macrophages (CD45 + CD14 + ) that inhibit T cell proliferation (30) .
The complexity of myeloid cells within human melanoma lesions remains poorly characterized with the phenotype relying on single or double marker detection by IHC and lack of immune-suppressive functional testing (31) and therefore, the importance of this cell type in T cell tolerance in human melanoma patients is unknown.
Our previous findings have identified regulatory elements that contribute to dampening tumorspecific T cells responses in melanoma tumors, such as PD-1 inhibitory receptor expression in tumorinfiltrating lymphocytes (32) and increased frequency of CD4 + CD25 + Foxp3 cells (33) . Building on these findings, and as a result of evidence supporting the suppressive role of myeloid-derived cells, we sought to investigate the frequency, phenotype and immune-suppressive function of the different myeloid subsets present in the blood and in tumors of patients with metastatic melanoma.
Materials and Methods

FACS analysis of blood and tumor samples
Tumor and blood specimens were collected from metastatic melanoma patients (patient characteristics specified in Table 1) , and blood samples were also collected from age and gender matched healthy Intracellular staining for the quantification of T regulatory cells was performed as previously described (33) .
Antibodies and reagents
The following monoclonal antibodies (mAbs) specific for human antigens and their corresponding isotype (L243(G46-6), APC-conjugated anti-CD15 (H198), Alexa-700-conjugated anti-CD14 (M5E2), and APCCy7-conjugated anti-CD11b (ICRF44). APC-conjugated anti-human FOXP3 antibody (236A/E7) and its isotype were purchased from eBioscience.
Isolation of blood and tumor-infiltrating myeloid cells
Whole blood and tumor samples from the same patient were processed as described. Myeloid cells were first enriched using positive selection with CD11b beads (Miltenyi Biotec) and then counted, stained with PI and anti-Lin (CD3, CD56, CD57, CD19, CD20), CD11b, CD14, CD15 and HLA-DR antibodies and PI negative cells (live cells) were sorted with FACS Aria (Becton Dickinson) using 100 µm nozzle. The purity (exceeded 90% except CD11b + CD15 int population from peripheral blood of patient #2 which was ≈ 60%) and viability of myeloid populations sorted was assessed by FACS after sorting procedure by adding PI to a small fraction of the sorted cells. Cytospins of the cell populations isolated were stained with a modified Wright-Giemsa stain using Diff-Quick (Siemens) to assess purity as well as morphology. Representative pictures were taken under 400X magnification.
In vitro proliferation assays
Autologous CD3 cells were isolated by negative selection from a ficolled blood preparation using Pan T cell isolation kit (Miltenyi) and labeled with 10 µM CFSE (Invitrogen) for 10 min at 37
• C. 60,000 CFSE labeled cells were stimulated with a 1:1 ratio of Dynabeads HumanT-Activator CD3/CD28 (Invitrogen) in
Complete Medium (CM: RPMI1640 with L-glutamine (Lonza) containing 10% human serum, antibiotics (penicillin 100 U/ml, streptomycin 100 μg/ml, gentamicin 10 μg/ml) in absence or presence of 60,000 live myeloid cells (counted after FACS sort by trypan blue exclusion) from the subpopulations separated. Cocultures were performed in duplicates. CFSE dilution was assayed at day 4 and the percent inhibition of proliferation exerted by a given myeloid population was calculated as = ((sample-control)/(non-stimulatedcontrol))*100; using the percent of cells that have not diluted CFSE from the sample (co-cultured with a given myeloid population), the positive control (no myeloid cells added) and the non-stimulated cells as a negative control.
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on sorting (FACS) of whole blood after hypotonic lysis of RBC from patients with melanoma (Mel; n=20) and healthy donors (HD; n=10) using all the previously mentioned markers. Figure 1A shows the representative dot plots for one of the patients included in the study to illustrate the gating strategy used.
In our work we consistently observed a previously undescribed subpopulation which expressed similar markers as neutrophils (
. Additionally, the CD15 int population showed a lower forward scatter, higher side scatter (not shown), and differences in expression of HLA-DR compared to the CD15 hi population, which lead us to study it as a distinct population. Figure 1B Table 2 and the frequency of each of the subsets within the myeloid cells is shown in Table 3 . Despite there were no differences in the percentage of CD14 + cells (13.8 ± 1.2 in healthy donors vs. 12.6 ± 1.1 in melanoma patients), the percentage of HLA-DR -cells within CD14 + cells was statistically increased ( Figure 1C ), reproducing differences in the frequency of this particular subset found in previous studies (22, 23) .
However, when these cells were represented as a percentage of all the live cells in peripheral blood in Figure 1D , In order to test whether the phenotypic classification of the subsets actually corresponded to different myeloid cell types in peripheral blood, we sorted these cells by FACS according to the expression of the previously mentioned cell surface markers and characterized them morphologically using Wright-Giemsa stains on cytospins ( Figure 2A) 
Myeloid cells infiltrating metastatic melanoma lesions are phenotypically heterogeneous
The existing literature related to cancer MDSC is largely based on murine models or myeloid cells from blood/bone marrow of cancer patients. In an effort to study the myeloid cells in the tumor microenvironment we assessed the expression of the same markers used to characterize blood myeloid cells (CD11b, CD14, CD15, HLA-DR) by FACS in the single cell suspensions obtained after enzymatic digestion of 26 freshly resected melanoma tumors. Cytospins and Wright-Giemsa stain of the cells isolated from one tumor digest is shown in Figure 2B . This tumor contained morphologically diverse cells including tumor cells (t), lymphocytes (l), and myeloid cells that could be identified as macrophages (m), eosinophils (e) and neutrophils (n) that could be efficiently enriched from the single cell suspension by separating them according to expression of CD14 + , CD14
-CD15 hi and CD14 -CD15 int , respectively. Figure   3A illustrates the gating strategy of one of melanoma samples studied. Myeloid cells (Lin -CD11b + cells)
were an infrequent population of cells infiltrating metastatic melanoma deposits ( Figure 3B ). The mean percentage of myeloid cells in the tumors (% Lin -CD11b + within all the live cells in the tumor after gating out aggregates, dead cells and RBCs) was 12.0 ± 3.5, and they were less prevalent than other tumorinfiltrating leucocyte populations (Supplementary Figure 1) . Notably, the phenotype of the myeloid cells in the tumor did not resemble the phenotype of peripheral blood myeloid cells ( Figure 3C and Table 3 (Table 3) , a marker that most probably reflects a more active and differentiated state.
Previous mouse and human studies have suggested that some myeloid derived cells could potentially inhibit T cell proliferation through Tregs induction (34, 35) . To study whether the presence of any of the Figure 3D) . Intriguingly, the percent of intratumoral CD15 + cells correlated with an increased frequency of Tregs, suggesting that perhaps granulocytic cells could inhibit T cell proliferation indirectly through induction of other inhibitory cells.
Melanoma-infiltrating myeloid cells display an impaired ability to inhibit in vitro T cell proliferation compared to peripheral blood myeloid cells
We next evaluated the ability of myeloid cells in blood and tumor to suppress T cell proliferation. We thus isolated by FACS sorting the previously mentioned myeloid subsets (those that could be isolated depending on the frequency for each particular sample) from peripheral blood and from the tumor of the same patient and co-cultured them with autologous CFSE labeled CD3 + cells stimulated non-specifically with anti-CD3/CD28 beads. The CFSE dilution of T cells co-cultured with blood and tumor-infiltrating myeloid cells isolated from one representative melanoma patient ( Figure 2 displays the purity and morphology of myeloid cells isolated) is shown in Figure 4 . Cumulative data assessing the suppressive activity of blood myeloid-derived subsets from 7 patients are represented in Figure 4D and summarized in Supplementary 
When we compared the suppressive activity of tumor-infiltrating myeloid cells to those in peripheral blood from the same patient, we found that these were unable to inhibit T cell proliferation ( Figure 4C for patient#2 and Figure 4D and Supplementary Table 2 
Discussion
Morphological, phenotypic and functional heterogeneity is a hallmark of myeloid-derived suppressor cells (MDSC)(2). However, this heterogeneity has also generated ambiguity in the definition of MDSC. Currently, one of the biggest limitations to address the importance of these cells in human cancer patients is the lack of more specific markers defining a suppressive population within monocytic and granulocytic myeloid cells. Despite several attempts to overcome this drawback, the use of markers such as CD124 (6) healthy donors and 10.5% ± 1.6 in melanoma patients). However, when determining the frequency of
CD14
+ HLA-DR -within all the live cells in peripheral blood (after RBC lysis) we found that there was a small yet not statistically significant increase (from 0.6% ± 0.1 to 1.1% ± 0.2) in patients with metastatic melanoma. Our data not only highlights the small difference in the percent of CD14 + HLA-DR -cells in melanoma patients compared to healthy donors, but also, and more importantly, the small frequency of these cells in peripheral blood.
There is only one article reporting the existence of suppressive granulocytic myeloid cells in peripheral blood of melanoma patients (25) . The authors describe a 4-fold increased frequency of neutrophils in melanoma patients (in their study characterized as CD11b + CD15 + cells; 20% for healthy controls and approximately 80% in stage III/IV melanoma patients)(25). We were not able to reproduce this remarkable difference between healthy donors and melanoma patients. However, a letter to the editor concerning this article reported that four independent laboratories were unable to reproduce some of the findings in this study (40) . This paper also reported that neutrophils rather than a mixed population of granulocytes (neutrophils and eosinophils) are responsible for inhibiting antigen-specific T cell proliferation. Our study provides evidence that the CD11b + CD15 + population includes not only neutrophils (CD11b + CD15 hi ) but also a less predominant eosinophil population with lower expression levels of CD15. Additionally, our results demonstrate that eosinophils can display a highly suppressive function, repeatedly more potent than neutrophils. Similar to other myeloid populations, eosinophils have been associated with local immune-stimulating and immune-suppressive activities depending on the microenvironment (41, 42) . Paraneoplasic blood hypereosinophilia is not common but has been reported in several non-solid malignancies (43) , and in contrast to tumor-associated tissue eosinophilia, is usually associated with aggressiveness and poor prognosis (44) . Recently, an increased frequency of immunesuppressive CD15 + CD16 -granulocytes in the peripheral blood of terminal cancer patients has been associated with poor prognosis and performance status (45) . The authors associate the suppressive activity of these cells to activated granulocytes, which down-regulate CD16 expression upon activation.
However, the CD15 + CD16 -phenotype is typical of eosinophils in the steady state, as these cells can be highly enriched and separated from neutrophils in peripheral blood by performing negative selection of 
CD16
+ cells (46) . Another recent work proposes CD244 as a specific marker to distinguish granulocytic MDSC from neutrophils in tumor-bearing mice (37) . Intriguingly, this marker is typically expressed in human eosinophils but not in neutrophils (47) . Our results uncover a potential contribution of eosinophils to the suppressive phenotype of Lin -CD11b + CD15 + granulocytic MDSC that has been commonly attributed to the more frequent neutrophil population.
One 
(IL-4, IL-13), have been postulated to promote tumor progression through secretion of angiogenic factors, growth factors, pro-invasive factors, and immune-suppression (49) . Indeed, culture of peripheral blood
CD34
+ progenitors cells in presence of cancer cell line supernatants in vitro resulted in an altered differentiation of dendritic cells (CD14 + cells) as they did not efficiently express HLA-DR and other markers of mature and differentiated antigen presenting cells (50, 51) . According to our data, melanomainfiltrating CD14 + cells expressed high levels of HLA-DR ( Figure 3A and Table 3 ). Perhaps this more differentiated phenotype, characterized by high HLA-DR expression, can account for the lack of suppressive function of these cells in melanoma tumors. The only evidence that we found supporting an indirect immune-regulatory role of tumor-infiltrating myeloid cells is the correlation between infiltrating granulocytic cells and T regulatory cells, but functional experiments will be required to further study the relevance of this association.
Overall, our results demonstrate that both monocytic cells and eosinophils from peripheral blood of melanoma patients are capable of inhibiting non-specific T cell proliferation. Despite expression of PD-1 and frequency of T regulatory cells were increased in melanoma-infiltrating lymphocytes as previously reported by our group (data not shown) (32, 33) , supporting other mechanisms of immune dysfunction in the population of melanoma patients studied, we did not observe any major differences in frequency and phenotype in any of the myeloid subsets in peripheral blood of patients with melanoma compared to healthy donors. Furthermore, in preliminary experiments we observed a similar ability to suppress T cell proliferation with myeloid cells obtained from two healthy donors tested (Supplementary Figure 2) . A heterogeneous myeloid population was found infiltrating melanoma tumors, but these cells were not capable of suppressing T cell proliferation. The lack of alterations in frequency of myeloid derived cells that we observed between melanoma patients and healthy donors contrast with the expansion of these cells reported in experimental models of cancer (3, 6, 27) . Possibly, the accumulation of myeloid derived suppressor cells is less evident in melanoma, a unique tumor capable of responding to immunotherapy (52, 53) . Divergence between fast-growing subcutaneously implanted tumors and the slow evolution of human tumors could also account for some differences. But perhaps, the biggest hurdle that will need to be overcome to address the importance of these cells in cancer patients is the lack of CD14+ and CD14-CD15+ within myeloid population were determined and correlation was assessed using a Spearman test. 
